UroGen Historical Valuation
| URGN Stock | USD 9.36 0.15 1.58% |
Some fundamental drivers such as market cap or UroGen Pharma enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze UroGen Pharma valuation indicators such as Market Cap of 224.6 M or Working Capital of 0.0 to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of UroGen Pharma's future value.
UroGen |
About UroGen Valuation Data Analysis
Valuation is the financial process of determining what UroGen Pharma is worth. UroGen Pharma valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. UroGen Pharma valuation ratios help investors to determine whether UroGen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UroGen with respect to the benefits of owning UroGen Pharma security.
UroGen Pharma Valuation Data Chart
Enterprise Value
Enterprise Value (or EV) is usually referred to as UroGen Pharma theoretical takeover price. In the event of an acquisition, an acquirer would have to take on UroGen Pharma debt, but would also pocket its cash. Enterprise Value is more accurate representation of UroGen Pharma value than its market capitalization because it takes into account all of UroGen Pharma existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.